Rukmini Priya Darsini Chowdavarapu

Apricots are a sweet summer-fruit staple and a wonderful addition to your diabetes meal plan. One apricot has just 17 calories and 4 g of carbohydrates. Four fresh apricots equal one serving and provide more than 50 percent of your daily vitamin A requirement. These fruity jewels are also a good source of fiber. Modern medicine is best for treating any disease in the same way traditional medicine should also be encouraged cause the traditional medicine is available at cheaper cost and said to be without any side effects. To support this anti diabetic activity of apricot kernels is performed. In this study alloxan induced diabetic activity model rat was used. First the kernels are authenticated then extracted using methanol. The methanol extracts showed the presence of alkaloids, tannins, flavonoids etc. which maybe the reason for anti-diabetic activity. Alloxan forms an increased glucose levels that generates diabetes. Post treatment with apricot kernel extract produced significant decrease in glucose levels indicating the therapeutic effect of extract. The method for testing glucose levels in blood is done by glucometer On treatment a dose dependent (low dose-100mg/kg, high dose-200mg/kg.) decrease in glucose levels were observed. For the low dose, the glucose level decreased to 150.1±17mg/dl by 7th day from 293.1±9.83mg/dl. For the high dose, the glucose level decreased to 125.7±20.7mg/dl by 7th day from 280.5±42.4mg/dl. However, the standard medicine metformin at the dose of 450mg/kg showed better results with 112.3±2.4mg/dl. Even though the extracts results are lower than the standard with further research and purification of extracts better results can be achieved.

Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer®. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. The aim of the present study was to develop sustained release formulation of Bosentan to maintain constant therapeutic levels of the drug for over 12 hrs. Various synthetic polymers were employed as polymers. Bosentan dose was fixed as 62.5 mg. Total weight of the tablet was considered as 200 mg. the tablets are prepared by employing direct compression method using 8mm punch. And the Polymers were used in the concentration of 31.5, 41.25, 62.5 mg concentration. All the formulations were passed various physicochemical evaluation parameters and they were found to be within limits. And the drug and excipient compatibility studies showed that there is no interaction between the drug and polymers employed in the formulation. Whereas from the dissolution studies it was evident that the formulation F3, F16 showed better and desired drug release pattern i.e., 98.15±0.06, 96.64±0.02 % respectively in 12 hours. the project work is successful in developing sustained release formulations of Bosentan.